[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.87.119.171. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 300
Citations 0
Clinical Trials Update
April 28, 2015

Hepatitis E Vaccine Effective for 4.5 Years

JAMA. 2015;313(16):1609. doi:10.1001/jama.2015.3855

The hepatitis E vaccine provided sustained protection against the virus for up to 4.5 years, found a follow-up study to a 2007 randomized trial that evaluated the short-term efficacy of the vaccine Hecolin. The initial phase 3 clinical trial randomly assigned 112 604 healthy adults aged 16 to 65 years in a 1:1 ratio to receive 3 doses of either a hepatitis E vaccine or a hepatitis B vaccine (the control group). The follow-up study assessed efficacy, immunogenicity, and safety for 54 months (Zhang J et al. N Engl J Med. 2015;372[10]:914-922).

First Page Preview View Large
First page PDF preview
First page PDF preview
×